Gubra A/S (GUBRA.CO)
ValueMarkers Composite Index
65% below intrinsic value ($154)
Gubra A/S (GUBRA.CO) — VMCI valuation read
Composite valuation read on GUBRA.CO: VMCI 75/100 against a Healthcare sector median of 50. The 25-point above-median print is the headline number for Gubra A/S, and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.
Trailing 30-day insider activity for GUBRA.CO: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.
**Investor frame.** Value, quality, risk in three lines on GUBRA.CO: GUBRA.CO trades at 19.0x earnings, 6% above the Healthcare median of 18.0x; ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%); net debt to EBITDA of 0.3x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.
GUBRA.CO rose 3.6% over the trailing 7 days, with a -16.2% read on a 30-day basis.
Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. The CRO segment offers pre-clinical contract research and development services for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, tissue research, assays, molecular pharmacology, bioanalysis, sequencing (NGS), and 2D and 3D imaging. The company was incorporated in 2008 and is based in Horsholm, Denmark.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.